Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | 10% owner | May 04, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hemab Therapeutics Holdings, Inc.
Report date May 04, 2026 · Filed May 14, 2026
Jointly reported with AI Biotechnology LLC, Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,876,344 |
Reported balance
Holding disclosure · report date 2026-05-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,876,344 F1: The securities reported are held directly by AI DEN-MAB LLC ("AI DMAB") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AIB"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH and AIB, (iii) AIH owns all of the voting units of AIB, and (iv) AIB owns all of the voting units of AI DMAB. Each of AIH, AIB, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported are held directly by AI DEN-MAB LLC ("AI DMAB") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AIB"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH and AIB, (iii) AIH owns all of the voting units of AIB, and (iv) AIB owns all of the voting units of AI DMAB. Each of AIH, AIB, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
No transactions match
Try broader filters. Historical coverage is still being backfilled.
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.